Through the activation of NF-κβ signaling, TNF-α (tumor necrosis factor-α) and IL-17 (interleukin-17) raise the expression of PD-L1 (programmed cell death protein 1) in LNCaP cells, hence promoting tumor cell motility and chemoresistance. Here, IL17A is linked to neoplasm.